Remember momelotinib? Gilead unloads shelved JAK inhibitor for token $3M payment from its former developers
About 6 years ago, Gilead $GILD paid $510 million in cash to bag YM BioSciences and its only drug — a once-promising JAK inhibitor later named …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
